Hayreh S S
Ocular Vascular Division, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, USA.
Indian J Ophthalmol. 2000 Sep;48(3):171-94.
Ischaemic optic neuropathy is of two types: anterior (AION) and posterior (PION), the first involving the optic nerve head (ONH) and the second, the rest of the optic nerve. Pathogenetically AION and PION are very different diseases. AION represents an acute ischaemic disorder of the ONH supplied by the posterior ciliary artery (PCA), while PION has no specific location in the posterior part of the optic nerve and does not represent an ischaemic disorder of any definite artery. The most important step towards a logical understanding of the underlying causes, clinical features, pathogenesis and rational management of AION, is to understand the basic scientific issues involved; these are discussed in some detail. AION clinically is of two types: (1) that due to giant cell arteritis (arteritic AION: A-AION) and (2) non-arteritic AION (NA-AION). NA-AION, the more common of the two, is one of the most prevalent and visually crippling diseases in the middle-aged and elderly, and is potentially bilateral. NA-AION is a multifactorial disease, with many risk factors collectively contributing to its development. Although there is no known treatment for NA-AION, reduction of risk factors is important in decreasing chances of involvement of the second eye and of further episodes. Our studies have suggested that nocturnal arterial hypotension is an important risk factor for the development and progression of NA-AION. The role of nocturnal arterial hypotension in the pathogenesis of NA-AION and management of nocturnal hypotension is discussed. Potent antihypertensive drugs, when used aggressively and/or given at bedtime, are emerging as an important risk factor for nocturnal hypotension, and there is some evidence that NA-AION may be occurring as an iatrogenic disease in some individuals. A-AION, by contrast, is an ocular emergency and requires immediate treatment with systemic corticosteroids to prevent further visual loss. The clinical parameters which help to differentiate the two types of AION, and their respective management are discussed.
前部缺血性视神经病变(AION)和后部缺血性视神经病变(PION),前者累及视神经乳头(ONH),后者累及视神经的其余部分。从发病机制上讲,AION和PION是截然不同的疾病。AION是由睫状后动脉(PCA)供血的视神经乳头的急性缺血性疾病,而PION在视神经后部没有特定位置,也不代表任何特定动脉的缺血性疾病。要从逻辑上理解AION的潜在病因、临床特征、发病机制和合理治疗,最重要的一步是了解其中涉及的基础科学问题;本文将对此进行详细讨论。临床上AION有两种类型:(1)由巨细胞动脉炎引起的(动脉炎性AION:A-AION)和(2)非动脉炎性AION(NA-AION)。NA-AION是两者中较常见的一种,是中老年人群中最普遍且致盲的疾病之一,并且可能是双侧性的。NA-AION是一种多因素疾病,许多危险因素共同导致其发生。虽然目前尚无已知的NA-AION治疗方法,但降低危险因素对于减少对侧眼受累及再次发作的几率很重要。我们的研究表明,夜间动脉低血压是NA-AION发生和进展的重要危险因素。本文将讨论夜间动脉低血压在NA-AION发病机制中的作用以及夜间低血压的管理。强效降压药在积极使用和/或睡前服用时,正成为夜间低血压的重要危险因素,并且有证据表明在某些个体中NA-AION可能是一种医源性疾病。相比之下,A-AION是一种眼科急症,需要立即使用全身糖皮质激素治疗以防止视力进一步丧失。本文将讨论有助于区分两种类型AION的临床参数及其各自的治疗方法。